CCS
SNDX icon

Concentric Capital Strategies’s Syndax Pharmaceuticals SNDX Stock Holding History

Concentric Capital Strategies’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21,944
Closed -$338K – 380
2025
Q3 		$338K Buy
+21,944
New +$287K 0.02% 284

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Concentric Capital Strategies's SNDX Position: Q4 2025 in Review

Concentric Capital Strategies sold out of Syndax Pharmaceuticals (SNDX) in Q4 2025, closing a stake of 21,944 shares — an estimated $338K sold.

Concentric Capital Strategies first reported a position in SNDX in Q3 2025 and held it in 1 quarter. The position peaked at $338K in Q3 2025. 229 funds tracked by Wall St. Rank hold SNDX as of Q4 2025.

  • Concentric Capital Strategies reported no remaining Syndax Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Concentric Capital Strategies sold 21,944 Syndax Pharmaceuticals shares in Q4 2025, an estimated $338K.
  • Concentric Capital Strategies first reported a position in Syndax Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Concentric Capital Strategies's Syndax Pharmaceuticals position peaked at $338K in Q3 2025.
  • 229 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2025.

Based on Concentric Capital Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.